Advanced search    

Search: authors:"Nicholas J. Wald"

11 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Erratum to: Quantifying the health benefits of chronic disease prevention: a fresh approach using cardiovascular disease as an example

0 Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London , Charterhouse Square, London EC1M 6BQ , UK - & Nicholas J. Wald

Occupational Exposure to Hydrazine and Subsequent Risk of Lung Cancer: 50-Year Follow-Up

Purpose Hydrazine is carcinogenic in animals, but there is inadequate evidence to determine if it is carcinogenic in humans. This study aimed to evaluate the association between hydrazine exposure and the risk of lung cancer. Methods The cause specific mortality rates of a cohort of 427 men who were employed at an English factory that produced hydrazine between 1945 and 1971 were...

Cost–benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke

The primary prevention of cardiovascular disease is a public health priority. To assess the costs and benefits of a Polypill Prevention Programme using a daily 4-component polypill from age 50 in the UK, we determined the life years gained without a first myocardial infarction (MI) or stroke, together with the total service cost (or saving) and the net cost (or saving) per year...

Quantifying the health benefits of chronic disease prevention: a fresh approach using cardiovascular disease as an example

Nicholas J. Wald 0 Joan K. Morris 0 0 N. J. Wald (&) J. K. Morris Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London

Incorporating DNA Sequencing into Current Prenatal Screening Practice for Down's Syndrome

Background Prenatal screening for Down's syndrome is performed using biochemical and ultrasound markers measured in early pregnancy such as the Integrated test using first and second trimester markers. Recently, DNA sequencing methods have been introduced on free DNA in maternal plasma, yielding a high screening performance. These methods are expensive and there is a test failure...

Randomised Trial of Text Messaging on Adherence to Cardiovascular Preventive Treatment (INTERACT Trial)

. Wald 0 0 Wolfson Institute of Preventive Medicine, Queen Mary University of London , Charterhouse Square, London EC1M 6BQ , United Kingdom OPEN ACCESS Abstract Citation: Wald DS, Bestwick JP, Raiman L

Prevention of Neural Tube Defects: A Cross-Sectional Study of the Uptake of Folic Acid Supplementation in Nearly Half a Million Women

Nicholas J. Wald 0 Cheryl S. Rosenfeld, University of Missouri, United States of America 0 Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary

Randomized Polypill Crossover Trial in People Aged 50 and Over

Background A Polypill is proposed for the primary prevention of cardiovascular disease in people judged to be at risk on account of their age alone. Its efficacy in reducing cholesterol and blood pressure is uncertain. Methods We conducted a randomized double-blind placebo-controlled crossover trial of a Polypill among individuals aged 50+ without a history of cardiovascular...

Screening for Future Cardiovascular Disease Using Age Alone Compared with Multiple Risk Factors and Age

screening. - Competing Interests: Nicholas J. Wald holds patents (EU1272220 and GB2361186) for a combination pill for the prevention of cardiovascular disease. This does not alter the authors adherence to

Antenatal Screening for Down Syndrome Using Serum Placental Growth Factor with the Combined, Quadruple, Serum Integrated and Integrated Tests

, Serum Integrated and Integrated Tests Nicholas J. Wald 0 Jonathan P. Bestwick 0 Lynne M. George 0 Wayne J. Huttly 0 Olga Y. Gorlova, The University of Texas M. D. Anderson Cancer Center, United States

Reconciling the Evidence on Serum Homocysteine and Ischaemic Heart Disease: A Meta-Analysis

Background Results from genetic epidemiological studies suggest that raised serum homocysteine is a cause of ischaemic heart disease, but the results of randomised trials suggest otherwise. We aimed to update meta-analyses on each type of study using the latest published data and test a hypothesis based on antiplatelet therapy use in the trials to explain the discrepancy. Methods...